Compare CRNX & FICO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | FICO |
|---|---|---|
| Founded | 2008 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 34.7B |
| IPO Year | 2018 | 1995 |
| Metric | CRNX | FICO |
|---|---|---|
| Price | $36.78 | $1,093.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 13 |
| Target Price | $76.75 | ★ $1,689.92 |
| AVG Volume (30 Days) | ★ 1.3M | 362.9K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.78 |
| EPS | N/A | ★ 17.73 |
| Revenue | $1,039,000.00 | ★ $1,032,475,000.00 |
| Revenue This Year | $720.10 | $27.28 |
| Revenue Next Year | $184.67 | $16.97 |
| P/E Ratio | ★ N/A | $61.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $870.01 |
| 52 Week High | $57.99 | $2,217.60 |
| Indicator | CRNX | FICO |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 53.68 |
| Support Level | $33.19 | $1,068.67 |
| Resistance Level | $37.23 | $1,117.39 |
| Average True Range (ATR) | 2.32 | 46.68 |
| MACD | -0.33 | 9.20 |
| Stochastic Oscillator | 13.52 | 76.85 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.